Optimizing Quality Tolerance Limits Monitoring in Clinical Trials Through Machine Learning Methods

Ziji Yu Co-Author
Takeda
 
Liwen Wu Co-Author
Takeda Pharmaceuticals
 
Rachael Liu Co-Author
Takeda Pharmaceuticals
 
Jianchang Lin Co-Author
Takeda
 
Lei Yan First Author
Florida State University
 
Lei Yan Presenting Author
Florida State University
 
Wednesday, Aug 6: 11:45 AM - 11:55 AM
1670 
Contributed Papers 
Music City Center 
The traditional clinical trial monitoring process, which relies heavily on site visits and manual review of accumulative patient data reported through Electronic Data Capture system, is time-consuming and resource-intensive. The recently emerged risk-based monitoring (RBM) and quality tolerance limit (QTL) framework offers a more efficient alternative solution to traditional source data verification based quality assurance. These frameworks aim at proactively identifying systematic issues that impact patient safety and data integrity. In this paper, we proposed a machine learning enabled approach to facilitate real-time, automated monitoring of clinical trial QTL risk assessment. Unlike the traditional quality assurance process, where QTLs are evaluated based on single-source data and arbitrary defined fixed threshold, we utilize the QTL-ML framework to integrate information from multiple clinical domains to predict the clinical QTL of variety types at program, study, site and patient level. Moreover, our approach is assumption-free, relying not on historical expectations but on dynamically accumulating trial data to predict quality tolerance limit risks in an automated manner.

Keywords

good clinical practice

risk-based monitoring

quality tolerance limits

machine learning 

Main Sponsor

Biopharmaceutical Section